News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Funding Round Brings in $49.1 Million for NeuroPace, Inc.


9/7/2011 8:58:35 AM

As it finishes up clinical trials and prepares to bring its implantable neurostimulation device to market, NeuroPace Inc. has raised $49 million of a funding round the company hopes will reach $60 million before it closes, investors in the company said. NeuroPace is using a neurostimulation technique to treat epilepsy, and is aimed at patients who have had little luck with anti-seizure medications. OrbiMed Advisors has raised $600 million for its first health-care royalties fund, double the amount the partners targeted for the pool. Selling royalty interests has caught on in recent years as medical companies have sought less-dilutive alternatives to equity. Other firms buying these interests include Cowen Healthcare Royalty Partners, Capital Royalty, Paul Capital Healthcare and Royalty Pharma.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES